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Background: The criteria for choosing relevant cell lines among a vast panel of available intestinal-derived lines
exhibiting a wide range of functional properties are still ill-defined. The objective of this study was, therefore, to
establish objective criteria for choosing relevant cell lines to assess their appropriateness as tumor models as well as
for drug absorption studies.
Results: We made use of publicly available expression signatures and cell based functional assays to delineate
differences between various intestinal colon carcinoma cell lines and normal intestinal epithelium. We have
compared a panel of intestinal cell lines with patient-derived normal and tumor epithelium and classified them
according to traits relating to oncogenic pathway activity, epithelial-mesenchymal transition (EMT) and stemness,
migratory properties, proliferative activity, transporter expression profiles and chemosensitivity. For example, SW480
represent an EMT-high, migratory phenotype and scored highest in terms of signatures associated to worse overall
survival and higher risk of recurrence based on patient derived databases. On the other hand, differentiated HT29
and T84 cells showed gene expression patterns closest to tumor bulk derived cells. Regarding drug absorption, we
confirmed that differentiated Caco-2 cells are the model of choice for active uptake studies in the small intestine.
Regarding chemosensitivity we were unable to confirm a recently proposed association of chemo-resistance with
EMT traits. However, a novel signature was identified through mining of NCI60 GI50 values that allowed to rank the
panel of intestinal cell lines according to their drug responsiveness to commonly used chemotherapeutics.
Conclusions: This study presents a straightforward strategy to exploit publicly available gene expression data to
guide the choice of cell-based models. While this approach does not overcome the major limitations of such
models, introducing a rank order of selected features may allow selecting model cell lines that are more adapted
and pertinent to the addressed biological question.
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Figure 1 Most dominant gene expression differences between
normal epithelium and all tumor-derived cell lines, and cells
with epithelial versus mesenchymal properties. Principal
component analysis (PCA) of genomic expression data from human
colon carcinoma cell lines (black); laser-dissected tissues (red) of
normal human colonocytes (LI), tumor cells (T) and small-intestinal
enterocytes (SI); primary cell cultures (green, CAFs); breast cancer cell
lines (grey). For each sample 2–3 three replicates were measured.
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A wide panel of intestinal cell lines is being used to study
the biology of the intestine. All of these cell lines are ei-
ther directly derived from primary colo-rectal cancers
(CRCs) of different clinical stages and differentiation
grades or from metastatic sites originated from a colon
tumor. The major oncogenic pathways in colon cancer in-
clude loss of function mutations in APC, TP53 and
SMAD4 (approximately 80–85% of sporadic tumors), or
DNA mismatch repair genes, and activating mutations in
beta-catenin [1]. As a consequence, the Wnt pathway is
activated in most tumors and derived CRC cell lines, al-
beit to a different extent, depending on the genetic lesions
[2-5]. The morphology, expression of differentiation mar-
kers, migratory characteristics and their potential to form
metastases differ vastly between the cell lines [5-8].
While cancer drug discovery has mainly focused on
targeting tumor cell proliferation, the outcome of a can-
cer depends largely on tumor invasion and dissemin-
ation [9]. Recent advances in understanding underlying
mechanisms in cancer biology including cancer stem cell
(CSC) properties and epithelial-mesenchymal transition
(EMT) and their relation to drug susceptibility require
that relevant traits are considered for choosing appropri-
ate cell-based models. It is believed that at the invasive
front, the tumor cells undergo EMT resulting in
increased migratory capacity. Furthermore, EMT has re-
cently been linked in breast cancer to stem cell like
properties [10] as well as resistance to chemotherapy in
different tumor types including CRC [11-14].
The variety of available human cancer cell lines reflects
the genomic heterogeneity across the human cancer
population at least in part and has therefore regained at-
tention notably to predict responsiveness of anticancer
drugs [15,16]. Starting with the landmark paper by Scherf
et al. [17] numerous studies followed that aimed at link-
ing drug response in terms of growth inhibition with
gene expression signatures, some specifically focusing on
colon cancer (e.g. [18-26]). To our knowledge, no study
has specifically focused on linking expression of malig-
nant traits (i.e. EMT, WNT activity, stemness signatures)
in colon cancer cell lines to response to therapy.
In this study we compare for the first time gene ex-
pression signatures relating to a wide panel of com-
monly known intestinal cell lines, primary cell cultures
of human cancer-associated fibroblasts and laser-
dissected human colonocytes, small intestinal entero-
cytes and tumor cells. We delineate selection criteria for
CRC derived cell lines based on genomic expression pat-
terns related to clinical parameters, migratory capacities
and proliferative activities. While some cell lines are
mainly being used to study mechanisms associated with
tumor biology others serve as models for normal enter-
ocytes studying drug absorption. Thus, we used thesame strategy to assess the validity of models for oral
drug absorption.Results
Most dominant gene expression differences as revealed
by principal component analysis (PCA) were observed be-
tween normal epithelium and all tumor-derived cell lines,
and cells with epithelial versus mesenchymal properties.
PCA was performed to assess the major gene expres-
sion differences between microdissected normal and
tumor epithelium, primary cancer-associated fibroblast
(CAF) cultures and the various CRC cell lines. PCA
involves a mathematical procedure that transforms a
number of possibly correlated variables into a smaller
number of uncorrelated variables called principal com-
ponents. Hence, the first principal component accounts
for as much of the variability in the data as possible and
each succeeding component accounts for as much of the
remaining variability as possible. Two breast cancer cell
lines with known pronounced (MB231) or weak (MCF7)
EMT traits [27] were included into the comparison. The
first component was defined mainly by the difference be-
tween small intestinal enterocytes and all CRC cell lines
grown to subconfluency, while the second component
was delineated by the difference between CAFs and epi-
thelial cells (Figure 1). T84, HT29 and Caco-2 cells
grown to confluency for 3 weeks seemed to be most
similar to the small intestinal enterocytes, and also to
laser-dissected tumor cells, while SW480 and MB231
proved closest to CAFs.
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based on expression of signatures related to
malignant traits
Next, the suitability of the various cell lines for tumor
biology related studies was assessed. There are no stand-
ard models and selection criteria are not well defined.
The activation of the Wnt pathway is a hallmark in
colon carcinogenesis. Recent findings indicate that the
Wnt activity defines CRC stem cells and is regulated by
the microenvironment [28]. Thus, the overall Wnt sig-
naling activity was compared in the various samples.Table 1 Rank order of cell lines according to their signature s
Cell Line EMT HuISC WNT Trans_BC SLC_SI3
CAF 1 1 8 29 24
MB231 2 2 23 30 30
COLO320 3 11 4 17 27
SW480 4 4 2 28 25
SW620 5 9 1 27 29
Tumor 6 3 3 20 8
Normal 7 10 26 12 7
Caco,Fl,D 8 15 14 6 6
Caco,Fl,U 9 7 6 5 11
Caco_CDX2,U 10 6 21 7 13
Caco_CDX2,D 11 25 25 3 3
JE 12 29 30 13 4
KM12 13 22 20 10 23
HCT116 14 12 24 21 26
Caco,Fi,D 15 26 27 2 2
T84 16 17 18 26 9
CacoReady 17 19 16 4 5
HT29,R 18 16 11 24 16
DLD1 19 13 5 9 18
Caco,S 20 27 15 23 22
HT29,S 21 18 13 18 15
MCF7 22 24 28 25 28
HT29,D 23 28 22 22 10
Caco,R 24 14 12 16 19
IL 25 30 29 1 1
HT29,U 26 23 19 19 14
LOVO 27 5 7 14 21
LS174T 28 8 10 15 12
COLO205 29 20 9 11 17
HCT15 30 21 17 8 20
EMT= EMT-related genes, HuISC=“Humanized intestinal stem cell signature”, WNT =
oral drug absorption, SLC_SI3 = solute carriers expressed at a significantly higher lev
the plasma membrane, ABC =ABC transporters, MKI67_CO: Set of genes correlating
with either strong positive or negative correlation between GI50 values of chemoth
Additional file 6, methods). Tumor = laser dissected tumor cells, Normal = laser disse
respectively, D = differentiated, U = undifferentiated, Fi = grown on filters, Fl = grownWhen comparing the average expression of direct Wnt
targets (i.e. 24 Wnt target genes relevant to human
colon and/or other cancers, with a proven direct tran-
scriptional control through TCF binding sites as
described in [29]), the SW620 cell line showed the stron-
gest Wnt signal followed by SW480, laser-dissected
tumor cells, COLO320, DLD1 and undifferentiated
Caco-2 cells (Table 1, detailed description of all gene sets
see supplementary data section “expression data ana-
lysis” and Additional file 1: Table S2). The ranking of cell
lines with strong, medium and low average expression oftrength
SLC_PM ABC MKI67_CO IC50_pos IC50_neg
23 30 24 6 7
29 27 10 10 21
28 10 4 4 29
27 17 17 24 12
22 20 8 7 26
24 26 23 5 20
14 9 27 2 18
5 6 21 8 13
6 2 13 16 1
7 7 18 11 23
3 4 28 29 14
12 22 29 3 30
11 21 2 13 5
25 18 14 9 24
2 5 26 17 19
17 29 22 22 25
4 1 20 15 10
10 13 5 25 3
15 24 3 18 2
20 11 9 28 6
13 12 1 20 4
30 25 15 14 28
21 16 25 26 8
18 8 7 27 11
1 3 30 1 27
9 23 16 30 17
16 19 6 12 15
26 28 19 23 16
8 15 12 21 22
19 14 11 19 9
direct Wnt targets, Trans_BC = Transporters known to play important role in
el in small intestinal samples versus colon samples, SLC_PM= solute carriers of
with MKI67 expression in colon cancer samples, IC50_pos, IC50_neg: Genes
erapeutics and expression across 60 cell line panel (for details of signatures see
cted colonocytes, JE, IL = laser dissected enterocytes of the jejunum or ileum,
in flasks, R = resistant to methotraxate, S = sensitive to methotrexate.
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ity based on TOPFLASH assays reported by Rosin-
Arbesfeld and co-workers [4]. Moreover, the expression
of genes involved in EMT ([29]) and a set of genes, re-
cently being described as “humanized intestinal stem cell
signature” (HuISC), which identified recurrent CRC [30],
were studied to rank the cell lines as models for tumor
cells at the invasive front and/or tumor cells with stem-
ness characteristics. Survival analysis studies showed that
risk of recurrence was significantly higher for CRC
patients with a strong EMT signature and also correlated
with overall survival (Figure 2). As expected CAFs and
MB231 (positive controls) had the strongest expression
of the EMT signature followed by COLO320, SW480,
SW620 and laser-dissected tumor epithelial cells, normal
colonocytes and differentiated Caco-2 cells. Though
COLO320 cells ranked highest of all intestinal epithelial
cells, they also had the highest expression of CDX2, a
key player in the maturation of intestinal enterocytes
[31]. When the cell lines were ranked to the overall ex-
pression of stem cell related genes (HuISC), the five top
ranked samples were CAF>MB231> laser-dissectedFigure 2 Signatures predictive for survival. Kaplan-Meier representation
over time for patients bearing colon cancers with average high (i.e. relative
expression< 0, red) of a selection of gene sets (details see Table 1).tumor cells> SW480>LOVO (Table 1). In summary,
with respect to the Wnt, EMT and HuISC signatures,
SW480 proved the cell line with the strongest traits and
a gene expression pattern most similar to that of micro-
dissected tumor epithelium.
Gain of malignant traits and loss of differentiation
signature were associated with migratory properties
Invasive tumor cells acquire higher motility through
EMT [9]. Thus, we elucidated to what extent genomic
expression characteristics could be linked to migratory
properties. In general, the analysis revealed that higher
migratory propensity was associated with strong EMT
traits and weak expression of a signature derived from
normal small intestinal epithelium (i.e. SLC_SI3). Ac-
cordingly, SW480 and MB231 cells showed the highest
migratory capacity (Figure 3).
Transporter profile defines absorption model
The model of choice to evaluate drug absorption are
Caco-2 cells as they undergo in vitro spontaneous enter-
ocytic differentiation by developing an apical brushof overall survival and recurrence-free survival (EMT_RFS) probability
average expression> 0, green) or low expression (i.e. relative average
Figure 3 Gain of malignant traits and loss of differentiation signature are associated with migratory properties. Migratory properties of
intestinal cell lines across membrane in the absence (motility) or presence (chemotaxis) of a FCS gradient (details see “Material and Methods”
section). Cell lines are ordered in dependence of rank orders of EMT and SLC_SI3 signatures as shown in Table 1.
Figure 4 Caco-2 cells most similar to small intestinal
enterocytes with respect to expression of solute carriers.
Principal component analysis (PCA) as shown in Figure 1, but carried
out on data set filtered using probe sets representing solute carriers.
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sucrase-isomaltase and aminopeptidase N [7,32-36]. On
the other hand, comparison of permeability coefficients
across different laboratories is still an issue [37]. Various
studies have compared the genomic profiles of Caco-2
cells to large and small intestinal tissue [5,38-40]. None
of these has systematically compared these profiles to
the ones of small intestinal enterocytes in comparison to
other intestinal cell lines, and, in particular, to profiles of
the genes relevant for active transport.
Consequently, we made use of our objective approach
to assess the suitability of the Caco-2 cells as model for
oral drug absorption as compared to other CRC derived
cell lines, taking inter-laboratory differences into ac-
count. As described above, PCA suggested that T84,
HT29 and Caco-2 cells grown to confluency for 3 weeks
were most similar to small intestinal enterocytes. Yet,
when performing PCA filtering on solute carriers, trans-
porters mostly responsible for active uptake, differen-
tiated Caco-2 cells emerged as most akin to small
intestinal enterocytes (Figure 4). When the analysis was
extended to include expression of drug transporters
known to be involved in uptake and secretion in the
small intestine (Trans_BC [41]), differentiated Caco-2
cells clustered with normal colonocytes as well as small
intestinal enterocytes (Figure 5). However, when focus-
ing only on transporters potentially relevant for uptake
(i.e. solute carriers expressed in plasma membrane accord-
ing to Gene Ontology, SLC_PM), differentiated Caco-2
cells clustered only with small intestinal enterocytes (Add-
itional file 2: Figure S1). When focusing on ABC transpor-
ters, differentiated Caco-2 cells clustered with HT29 and
T84 cells (Additional file 3: Figure S2), suggesting thatthese cell lines could also serve as a model for active ex-
port. Focusing on the expression of SLCs specific for the
small intestine (i.e. SLC_SI3: SLCs expressed≥ two fold in
small intestine versus normal pool samples), differentiated
Caco-2 cells, however, ranked highest independent of cul-
ture conditions and origins (Table 1).
Selection criteria for chemo-sensitivity studies
Recent reports suggest that chemotherapy may lead to a
selection of tumor cells with EMT and stem cell proper-
ties and increased chemo-resistance [12]. For example,
Gupta et al. [11] suggested that treatment with paclitaxel
as compared to salinomycin significantly enriched breast
Figure 5 Drug transporter profiles of small intestinal enterocytes most similar to Caco-2 cells. Heatmap of the relative expression levels of
transporters known to be relevant for oral drug absorption (Trans_BC). Tumor = laser dissected tumor cells, Normal = laser dissected colonocytes,
JE, IL = laser dissected enterocytes of the jejunum or ileum, respectively, D = differentiated, U = undifferentiated, Fi = grown on filters, Fl = grown in
flasks. Detailed description of samples in Additional file 5: Table S1.
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their data set (GEO, GSE17215) and found that our
EMT signature was also significantly enriched when per-
forming GSEA (p = 0.000, FDR=0.000, normalized en-
richment score = 2.01). Using the same approach,
however, we could not observe any significant enrich-
ment (i.e. p< 0.05) of this EMT signature in either
oxaliplatin-treated HT29, DLD1 and LOVO cells (GEO,
GSE10405), or methotrexate-treated HT29 and Caco-2
cells (GEO, GSE16648) as compared to untreated cells.
Of note, however, that the stem cell signature HuISC was
enriched in methotrexate treated Caco-2 cells (p = 0.000,
FDR=0.000, normalized enrichment score = 2.08).
To extend this analysis we addressed more compre-
hensively to what extent EMT, HuISC and WNT signa-
tures correlated with GI50 values of 50 commonly used
chemotherapeutics in the NCI60 cell line panel (http://
dtp.nci.nih.gov/docs/cancer/cancer_data.html).
Unexpectedly, no correlation between expression of
EMT, HuISC and Wnt signatures and GI50 values was
observed (Figure 6A), and furthermore, rank orders in
terms of EMT, HuISC and Wnt signatures of 6 CRC celllines comprised within the NCI60 panel (Table 1) did
not reveal any positive correlation with GI50 values, yet
even a tendency to a negative link (Figure 6B).
Most chemotherapeutics interfere with the cell cycle
activities and accordingly cell proliferation has been
associated with susceptibility to chemotherapy [42]. As
expected, a positive correlation between expression of
proliferation associated genes and GI50 values was
observed across the NCI60 cell lines (Figure 6A). The
CRC cell lines tested herein (Table 1) displayed no sig-
nificant difference in proliferation (data not shown) and
no link was observed between their rank orders (Table 1)
and GI50 values (Figure 6B).
Finally, we scrutinized the NCI60 data sets for genes
whose expression was either positively or negatively cor-
related with GI50 values of chemotherapeutics (i.e. for at
least three compounds correlation coefficient> |0.5|).
Clustering of the correlation coefficients revealed two
distinct gene sets (Additional file 4: Figure S3) for which
the median positive and negative correlation coefficients
were determined (Figure 6A). Interestingly, a link could
be observed between rank orders of the CRC cell lines
Figure 6 Expression of EMT and HuISC gene sets do not correlate with GI50 values, but with a signature defined by mining NCI
databases. Boxplots of the median correlation coefficients between –log (GI50) values and (A) expression of various gene sets in the NCI60 cell
line panel or (B) rank orders according to Table 1 of the six intestinal cell lines represented in the NCI60 panel (i.e. SW620, HCT116, HCT15,
COLO205, KM12, HT29). Gene sets as described in Table 1.
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these new signatures might be worth pursuing for asses-
sing chemo-sensitivity.
Discussion
Selection criteria for cell-based models are often ill
defined and arbitrary. Here we propose to make use of
publicly available data generated by high throughput
technologies to guide the choice of cell lines according
to more objective criteria, such as gene expression sig-
natures for selected traits. Focusing on CRC cell lines,
we validated this approach for three different fields of
application, i.e. the identification of cell lines most rele-
vant for modeling and investigating tumor cell invasion,
drug absorption and/or transport, and response to
chemotherapy. Though we have focused on specific se-
lection criteria, our strategy may be applied to any type
of selection criteria (i.e. gene sets of different pathways
and/or properties).
Models to study tumor biology
In view of the heterogeneity of solid tumors [9,43] and
the challenge to identify adequate cell-based models, we
assessed to what extent comparative data mining for
identifying tumor traits that overlap in tumor samples
and cell lines might contribute to improving the rele-
vance of cell-based models. We therefore ranked a panel
of CRC cell lines using EMT and HuISC signatures to
assess to what extent such signatures reflect invasive
tumor behavior. Reports on in vivo studies with these
cell lines indeed validate our ranking criteria. Thus,
SW480, SW620, COLO320 and HCT116 cells, which
all ranked high in our assessment for EMT and HuISC
signatures, showed the highest propensity for local inva-
sion upon orthotopic grafting [6,8], whereas HT29,
COLO205 and DLD1, which ranked lower for thesetraits, showed less aggressive behavior. De Vries and co-
workers observed that SW620 cells were indeed strongly
invasive in vitro, in vivo, however, they proved less inva-
sive than HT29 and LS174T cells [44]. Collectively, un-
biased data mining allowed identifying cell lines with
prominent mesenchymal traits (e.g. SW480), which dis-
play migratory properties and represent an invasive
phenotype, whereas HT29, the most frequently used
CRC model line, and T84 cells, which both ranked low
for these traits came closest to gene expression profiles
of bulk tumor tissue cells (Figure 1 and Table 1).
Caco-2 cells, a model of choice for drug absorption
Screening the literature with key words such as “absorp-
tion” and “transporters” revealed that, within the CRC
cell line panel assessed herein, Caco-2 is the most widely
used intestinal cell line for absorption-related studies
[45-47]. Comparing transporter gene expression profiles
revealed that differentiated Caco-2 cells indeed most ac-
curately recapitulate those of normal enterocytes. Similar
to Hayeshi et al. [37], we observed that culture condi-
tions influence the expression pattern of selected trans-
porters. Based on our ranking method we show that
Caco-2 cells grown for three weeks, independently of
their origin and culture conditions, best match the gen-
omic profiles of small intestinal enterocytes.
Chemo-sensitivity
Selection of tumor cells with EMT and stem cell proper-
ties and higher chemo-resistance has recently emerged
as a novel mechanism underlying therapy-resistance
[10-12,48,49]. Vast databases with GI50 values, a stand-
ard to assess drug sensitivity [15,16], are available for
the intestinal CRC lines HT29, COLO205, KM12,
SW620, HCT116, HCC_2998 and HCT15 through the
NCI database (http://dtp.nci.nih.gov/docs/cancer/cancer_
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relation between EMT and CSC signatures and chemore-
sistance. Using the EMT signature defined herein, we
could indeed confirm such a correlation in the breast
cancer data set of Gupta et al. [11]. However, we could
not observe any significant association of EMT-related
genes with the GI50 values of CRC cell lines (Figure 6).
Interestingly, novel chemoresistance-associated signa-
tures could be identified; indicating that in CRC cell lines
expression of EMT and CSC signatures are not dominant
factors in the response to therapy. Cell line- or treatment-
specific effects may account for this discrepancy. It is of
note that Gupta and co-authors compared paclitaxel vs.
salinomycin-treated cells, while the other data were based
on treatment versus non-treatment comparisons.
A correlation between drug resistance and EMT fea-
tures has, however, been observed using CRC biopsies
[13,14]. As these may contain variable amounts of stroma
and as stroma content may influence response to therapy
[50], these data are not directly comparable to GI50
values of CRC cell lines.
Conclusions
We have presented a straightforward strategy to exploit
publicly available gene expression data to guide the
choice of cell-based models. While this approach does
not overcome the major limitations of such models,
introducing a rank order of selected features may allow
selecting model cell lines that are more adapted and per-
tinent to the addressed biological question. In summary,
we conclude that SW480 represent an EMT-high, migra-
tory phenotype and scored highest in terms of signatures
associated to worse overall survival and higher risk of re-
currence based on patient derived databases, therefore a
good model to study invasive tumor cells. On the other
hand, differentiated HT29 and T84 cells showed gene
expression patterns closest to tumor bulk derived cells.
Regarding drug absorption, we confirmed that differen-
tiated Caco-2 cells are the model of choice for active up-
take studies in the small intestine.
Methods
Cell culture
Cell culture media were as follows: SW480, RPMI 1640,
10% fetal calf serum (FCS); Caco-2, Dulbecco’s modified
Eagle essential medium (DMEM) Glutamax, 10% FCS,
1% non-essential amino acids; HT29, LS174T, DMEM
Glutamax, 10% FCS; T84, RPMI 1640, 10% FCS, 2 mM
glutamine. Primary fibroblasts, DMEM Glutamax, 10%
FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, pt?
>0.5 mL gentamycin (50 mg/mL). All cell lines were cul-
tured at 37°C and 5% CO2 (Samples 15–29 see Additional
file 5: Table S1). CDX2-shCaco-2 cells were maintained
under puromycin selection (2 ug/mL) (Samples 86–88 seeAdditional file 5: Table S1). RNA was extracted using
Nucleo-Spin RNA-extraction kit from Machery-Nagel
(Oensingen, Switzerland). CacoReadyTM kit cells (Ready-
cell, Barcelona, Spain) were cultured on 24-transwells
filters for either 14 days in DMEM low glucose contain-
ing 10% FCS, 1%L-glutamine and 100 U/ml penicillin,
100 μg/ml streptomycin, then 4 days of culture in semi-
solid shipping media and again 3 days in culture media
(Readycell’s patented technology) (Samples 54–56 see
Additional file 5: Table S1), or for 3 weeks in the absence
of the semi-solid shipping media (Samples 57–59 see
Additional file 5: Table S1). Differentiated Caco-2LD
cells were grown at low density and then differentiated
on 0.4 μm PET filters as described earlier [51] (Samples
49–51 see Additional file 5: Table S1).
Laser dissection microscopy
Immediately after resection of human tissue, samples
were put on ice and sections of one cm length of small
intestine and colon (tumor regions and adjacent normal
epithelium), respectively, were cut, washed in chilled
PBS, embedded in OCT and frozen immediately. One
section of the ileum und two of the jejunum were first
stored in RNAlater at 4°C for shipping, then rinsed with
chilled PBS and embedded in OCT and frozen immedi-
ately. 12 μm frozen sections were cut and mounted on
Leica or Zeiss membranes for dissecting microscopy
(Leica Microsystems, Germany and PALM Microbeam,
Germany), fixed in 96% ethanol for 30 s and colored for
an equivalent time with hematoxylin/eosin solution, re-
spectively. Membranes were then rinsed in water for
30 s, transferred for 10 s to 70% ethanol, followed by
96% ethanol and air-dried. Frozen samples were pro-
cessed using a laser dissecting microscope coupled to a
CCD camera (Leica Microsystems, Germany and PALM
Microbeam, Germany). For each patient sample dissected
cells were pooled in a tube cap containing 20 μL RNA
lysis buffer. Collection of human intestinal samples was
approved by the corresponding local ethic commission
(Samples 1–6, 10–14 see Additional file 5: Table S1).
Gene expression using GeneChipW human genome U133
plus 2.0
Total RNA was extracted using the total RNA extraction
Nucleospin II kit by Machery-Nagel (Oensingen, Switz-
erland). The quality and quantity of all RNA samples
was examined by the Agilent 2100 Bioanalyzer (Agilent
Biotechnologies, Germany) and by a NanoDrop (Witec
AG, Switzerland), respectively. RINs for cell lines were
between 9 and 10, for LDM material between 5 and 7
except for two small intestinal samples. 100 ng of total
RNA were used as the starting material for all individual
samples. Labeling and fragmentation of cRNA, array
hybridization and scanning was performed according to
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Cell lines were measured in triplicates with different
passage numbers. Normal tumor intestinal human tissue
was obtained from different individuals. The complete
data set is publicly available at http://www.ncbi.nlm.nih.
gov/geo/ through the accession number GSE30292.
Migration and proliferation assay
Chemotaxis was assayed in 48-well Boyden microcham-
bers (Neuro Probe, Cabin John, MD, USA). Cells were
cultured in serum-free media overnight. For the migra-
tion studies, chemotaxis buffer containing 30% serum
was placed in the lower wells, and 104 cells, suspended in
chemotaxis buffer (culture media with 1% BSA), in the
upper wells. A PVPF membrane (Poretics 25 × 80 mm)
with 8 μm pores was coated with rat collagen type I.
After 15 h of incubation the membrane was removed,
washed on the upper side with PBS, fixed and stained
with Diff-Quick staining kit. Migrated cells were counted
at 1000-fold magnification in five randomly selected
fields. Values are given as average cell count of five high-
powered fields (5 HPF). Proliferation was assessed using
an MTT assay (Sigma-Aldrich, Switzerland) over five
days. Briefly, 3000 cells were seeded in five replicates per
day, per well in a 96-well plate. At each time point 10 μL
MTT working solution was added to each well. Then the
plate was incubated for 3 h at 37°C and the cells lysed
with lysis buffer overnight. Optical density was mea-
sured at 540 nm. ANOVA was done for migration data
(p value ≤ 0.05).
Public data
Publicly available data was obtained at http://www.ncbi.
nlm.nih.gov/geo/ through the accession numbers
GSE2361, GSE2361, GSE7303 (Pool normal; colon
GSM175905, small intestine GSM175908, lung
GSM176012, breast GSM175792, prostate GSM175923,
uterus GSM175945, kidney GSM175911), GSE2109 (Pool
tumor; colon GSM38055, small intestine GSM38068, lung
GSM38051, breast GSM38051, prostate GSM38053,
uterus GSM38052, kidney GSM38073), GSE10843,
GSE13059, GSE16648, GSE22572. MB231 and MCF7 cell
lines (GSE10890) were included in the analysis as controls
for cells with strong EMT properties and with weak, re-
spectively. Expression data for NCI60 cell line panel was
obtained through http://discover.nci.nih.gov/cellminer/
[52] and GI50 data at http://dtp.nci.nih.gov/docs/cancer/
cancer_data.html.
Expression data analysis
Robust multi-array averaging (RMA) and quantile
normalization were used to quantify gene expression.
Significant differences were identified applying a Bayes-
ian approach using the limma package (R 2.12.0,Bioconductor 2.7). A threshold of an adjusted p value≤
0.05 was used to identify significant changes if not indi-
cated otherwise. Gene set enrichment analysis (GSEA)
was carried out according to Subramanian et al. [53] and
p values were computed using a bootstrap distribution
created by resampling gene sets of the same cardinality.
See details in supplementary data section “expression
data analysis” and Additional file 1: Table S2 regarding
data sets. Principle component analysis was performed
using the affy package (R, Bioconductor). Correlation
coefficients between –log(GI50) of selected drugs (see
Additional file 6) and normalized expression values were
calculated using R. Heatmaps were generated using Clus-
ter 3.0 and TreeView (http://rana.lbl.gov/EisenSoftware.
htm) [54]. Centered correlation or Spearman rank cor-
relation and average linkage clustering, respectively, were
used for similarity measurement and clustering. Effects
of signatures on overall and recurrence free survival were
studied using the Kaplan-Meier survival curves and log
rank tests in three different publicly available data sets
(GSE12945, GSE14333, GSE17537) using the survival
package in the statistical software R version 2.13.0. Pa-
tient samples were divided into two groups splitting at
the average score.Ranking according to signature strength
Gene expression data was filtered by selecting only one
probe set, the one with the highest standard deviation
across all samples, per gene. For each gene of a given
gene set the relative expression (i.e. gene-wise zero-
centering of expression values) across all samples was
determined. The score of a gene set was calculated as
the average of the expression values of the genes in the
set. The cell lines were then ranked according to this
score. See details in supplementary data section “expres-
sion data analysis” and Additional file 1: Table S2 regard-
ing data sets.Drug sensitivity analysis
Correlation coefficients between –log(GI50) and log2
gene expression values were calculated for a panel of 50
chemotherapeutics (CTX, list of drugs see Additional file
7: Figure S4) and a panel of drugs (NSC) for which for
all 59 cell lines GI50 values were available and SD across
59 lines of –log(GI50) was> 0.Additional files
Additional file 1: Table S2. Gene sets used for data analysis.
Additional file 2: Figure S1. Solute carriers of plasma membrane
profiles of small intestinal enterocytes most similar to Caco-2 cells.
Heatmap of relative expression levels of solute carriers of the plasma
membrane.
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http://www.biomedcentral.com/1471-2164/13/274Additional file 3: Figure S2. Differentiated Caco-2, HT29 and T84
cell lines most similar to enterocytes with respect to expression
ABC transporters. Heatmap of the relative expression levels of ABC
transporters.
Additional file 4: Figure S3. Two distinct groups of genes with
respect to expected chemosensitivity. Heatmap of correlation
coefficients –log(GI50) of 50 chemotherapeutics and expression values
across the NCI60 cell line panel.
Additional file 5: Table 1S. List of expression files used for
microarray analysis and corresponding accession numbers at Gene
Expression Omnibus.
Additional file 6: Supplementary information for methods and
additional results [29,30,41,55-58].
Additional file 7: Figure S4. Enrichment of small intestinal signature
in Caco-2 cells upon differentiation. Heatmap representing enrichment
scores obtained by gene set enrichment analysis of the selected panel of
gene sets. Genes in the various cell lines were ranked according to their
relative average expression (n = 2-3) in the given cell line compared to a
panel of healthy epithelial tissues. Details see Additional file 6, material
and methods.
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